Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Inna Dabisch, Jürgen Dethling, Charalabos-Markos Dintsios, Melanie Drechsler, Daniel Kalanovic, Peter Kaskel, Frank Langer, Jörg Ruof, Thorsten Ruppert, Daniel Wirth

ABSTRACT

The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology. JEL CODES: D61; H51; I18. More... »

PAGES

2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/2191-1991-4-2

DOI

http://dx.doi.org/10.1186/2191-1991-4-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016863946

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24460706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dabisch", 
        "givenName": "Inna", 
        "id": "sg:person.01074334156.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074334156.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420105.2", 
          "name": [
            "GlaxoSmithKline GmbH & Co., Munich, KG, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dethling", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.01352546532.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352546532.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dintsios", 
        "givenName": "Charalabos-Markos", 
        "id": "sg:person.01004341263.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004341263.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Boehringer Ingelheim (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420061.1", 
          "name": [
            "Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, KG, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Drechsler", 
        "givenName": "Melanie", 
        "id": "sg:person.01247654747.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247654747.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476393.c", 
          "name": [
            "Pfizer Pharma GmbH, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalanovic", 
        "givenName": "Daniel", 
        "id": "sg:person.0720442760.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720442760.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476255.7", 
          "name": [
            "MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540, Haar, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaskel", 
        "givenName": "Peter", 
        "id": "sg:person.0773616073.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773616073.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.435900.b", 
          "name": [
            "Lilly Deutschland GmbH, Bad Homburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Langer", 
        "givenName": "Frank", 
        "id": "sg:person.01307316670.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307316670.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.424277.0", 
          "name": [
            "Roche Pharma AG, Grenzach-Wyhlen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruof", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.01246054426.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246054426.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruppert", 
        "givenName": "Thorsten", 
        "id": "sg:person.0763746656.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763746656.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wirth", 
        "givenName": "Daniel", 
        "id": "sg:person.01310476327.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.15.3510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002585977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002899527", 
          "https://doi.org/10.1038/leu.2009.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002899527", 
          "https://doi.org/10.1038/leu.2009.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00371-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008444022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008467674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008467674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010709152", 
          "https://doi.org/10.1038/sj.bjc.6601986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010709152", 
          "https://doi.org/10.1038/sj.bjc.6601986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012612445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.317.7161.771", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015749208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017750913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urolonc.2015.03.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017967707"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djp369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019709167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024607483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024607483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.5558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025698429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00120-011-2713-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026621978", 
          "https://doi.org/10.1007/s00120-011-2713-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3747/co.v18is2.941", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030292939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1999.00202.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030326537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031646383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-010-0218-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035704636", 
          "https://doi.org/10.1007/s10198-010-0218-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038028713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.9867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038250497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.6796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038707957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clon.2004.06.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042113450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2011-10-383711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043265594"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2013.145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045286767", 
          "https://doi.org/10.1038/bjc.2013.145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-9536(94)90151-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046445641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2007.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048555210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1752-1947-5-429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051791591", 
          "https://doi.org/10.1186/1752-1947-5-429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-s1-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052046724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa022457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052596157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-012-1417-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053663300", 
          "https://doi.org/10.1007/s00520-012-1417-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.99.078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.99.089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077138395", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078165983", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083397220"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology.\nJEL CODES: D61; H51; I18.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/2191-1991-4-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1046836", 
        "issn": [
          "2191-1991"
        ], 
        "name": "Health Economics Review", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany", 
    "pagination": "2", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5059aedfb2fd46020670ba7fc5137a9a7a6637c4781eb40204db5beb2796f9fe"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24460706"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101583209"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/2191-1991-4-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016863946"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/2191-1991-4-2", 
      "https://app.dimensions.ai/details/publication/pub.1016863946"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000549.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F2191-1991-4-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      21 PREDICATES      67 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/2191-1991-4-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N32fcb6d187ec47b5bcf834a34a7859ed
4 schema:citation sg:pub.10.1007/s00120-011-2713-5
5 sg:pub.10.1007/s00520-012-1417-8
6 sg:pub.10.1007/s10198-010-0218-6
7 sg:pub.10.1038/bjc.2013.145
8 sg:pub.10.1038/leu.2009.38
9 sg:pub.10.1038/sj.bjc.6601986
10 sg:pub.10.1186/1752-1947-5-429
11 https://app.dimensions.ai/details/publication/pub.1077138395
12 https://app.dimensions.ai/details/publication/pub.1078165983
13 https://doi.org/10.1002/ijc.25423
14 https://doi.org/10.1016/0277-9536(94)90151-1
15 https://doi.org/10.1016/j.clon.2004.06.023
16 https://doi.org/10.1016/j.urolonc.2015.03.015
17 https://doi.org/10.1016/j.ygyno.2007.06.005
18 https://doi.org/10.1016/s0140-6736(11)61613-9
19 https://doi.org/10.1016/s0959-8049(01)00371-9
20 https://doi.org/10.1046/j.1464-410x.1999.00202.x
21 https://doi.org/10.1056/nejmoa022457
22 https://doi.org/10.1093/annonc/mdj023
23 https://doi.org/10.1093/annonc/mdq204
24 https://doi.org/10.1093/annonc/mdr362
25 https://doi.org/10.1093/jnci/djp369
26 https://doi.org/10.1093/jnci/djq029
27 https://doi.org/10.1136/bmj.317.7161.771
28 https://doi.org/10.1177/1352458512448449
29 https://doi.org/10.1177/1352458512451660
30 https://doi.org/10.1182/blood-2011-10-383711
31 https://doi.org/10.1185/030079905x74862
32 https://doi.org/10.1200/jco.2003.99.078
33 https://doi.org/10.1200/jco.2003.99.089
34 https://doi.org/10.1200/jco.2007.10.8407
35 https://doi.org/10.1200/jco.2007.13.6796
36 https://doi.org/10.1200/jco.2007.15.3510
37 https://doi.org/10.1200/jco.2011.39.5558
38 https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502
39 https://doi.org/10.1200/jco.2012.45.9867
40 https://doi.org/10.1634/theoncologist.2010-s1-13
41 https://doi.org/10.3747/co.v18is2.941
42 schema:datePublished 2014-12
43 schema:datePublishedReg 2014-12-01
44 schema:description The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology. JEL CODES: D61; H51; I18.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree true
48 schema:isPartOf N608f3771cdf94fbb91435ef948a9c0ca
49 N83c2367c28f24501aab3f7bb98859ae5
50 sg:journal.1046836
51 schema:name Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
52 schema:pagination 2
53 schema:productId N1f9ea08cc92f46e7b9eb0b77f4d4afe6
54 N7743a0a4a51d46cebf745c975db7ad25
55 N96f6ffb5b23b4c278685e15655d7aafc
56 Naf7ba3bef4764726b8acaff94008ce6f
57 Nafc7fa09dac147fdb72b41275fc26848
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016863946
59 https://doi.org/10.1186/2191-1991-4-2
60 schema:sdDatePublished 2019-04-10T19:15
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N4e722857455d418fa8df70f12c8ead0c
63 schema:url http://link.springer.com/10.1186%2F2191-1991-4-2
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N081a0a01724644d6baf2478e22a0e59e rdf:first sg:person.0720442760.21
68 rdf:rest Nbf83512bc1fa456d8f787bf9ee577093
69 N1f9ea08cc92f46e7b9eb0b77f4d4afe6 schema:name pubmed_id
70 schema:value 24460706
71 rdf:type schema:PropertyValue
72 N22299989f4db48e285f5d83ab0e48d09 rdf:first sg:person.01310476327.89
73 rdf:rest rdf:nil
74 N22750a82adf54f35881a0a216b9f07f7 rdf:first sg:person.01307316670.12
75 rdf:rest Ndd960f3027a44487bd4d5714dcebb032
76 N26b7a6d22b0e4f659fdbd3b0485815a5 schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
77 rdf:type schema:Organization
78 N32fcb6d187ec47b5bcf834a34a7859ed rdf:first sg:person.01074334156.67
79 rdf:rest Neec6557a161f483db6ae62d4207cffeb
80 N4e722857455d418fa8df70f12c8ead0c schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 N608f3771cdf94fbb91435ef948a9c0ca schema:volumeNumber 4
83 rdf:type schema:PublicationVolume
84 N7743a0a4a51d46cebf745c975db7ad25 schema:name readcube_id
85 schema:value 5059aedfb2fd46020670ba7fc5137a9a7a6637c4781eb40204db5beb2796f9fe
86 rdf:type schema:PropertyValue
87 N83c2367c28f24501aab3f7bb98859ae5 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 N897522cae90341cba5ee6131db831777 rdf:first sg:person.01004341263.95
90 rdf:rest Nbbfeae97537b4f7081e17e744667ee6a
91 N96f6ffb5b23b4c278685e15655d7aafc schema:name dimensions_id
92 schema:value pub.1016863946
93 rdf:type schema:PropertyValue
94 Naf7ba3bef4764726b8acaff94008ce6f schema:name nlm_unique_id
95 schema:value 101583209
96 rdf:type schema:PropertyValue
97 Nafc7fa09dac147fdb72b41275fc26848 schema:name doi
98 schema:value 10.1186/2191-1991-4-2
99 rdf:type schema:PropertyValue
100 Nb68db0010def4b31a1cb657f3857b9e6 rdf:first sg:person.0763746656.45
101 rdf:rest N22299989f4db48e285f5d83ab0e48d09
102 Nbbfeae97537b4f7081e17e744667ee6a rdf:first sg:person.01247654747.73
103 rdf:rest N081a0a01724644d6baf2478e22a0e59e
104 Nbf83512bc1fa456d8f787bf9ee577093 rdf:first sg:person.0773616073.80
105 rdf:rest N22750a82adf54f35881a0a216b9f07f7
106 Ndd960f3027a44487bd4d5714dcebb032 rdf:first sg:person.01246054426.47
107 rdf:rest Nb68db0010def4b31a1cb657f3857b9e6
108 Neec6557a161f483db6ae62d4207cffeb rdf:first sg:person.01352546532.30
109 rdf:rest N897522cae90341cba5ee6131db831777
110 Nf3051a53137941a396043d862a62ce2b schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
111 rdf:type schema:Organization
112 Nfc6445ffdaab4d468f1fb4d85ee1b88f schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
113 rdf:type schema:Organization
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
118 schema:name Oncology and Carcinogenesis
119 rdf:type schema:DefinedTerm
120 sg:journal.1046836 schema:issn 2191-1991
121 schema:name Health Economics Review
122 rdf:type schema:Periodical
123 sg:person.01004341263.95 schema:affiliation Nfc6445ffdaab4d468f1fb4d85ee1b88f
124 schema:familyName Dintsios
125 schema:givenName Charalabos-Markos
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004341263.95
127 rdf:type schema:Person
128 sg:person.01074334156.67 schema:affiliation N26b7a6d22b0e4f659fdbd3b0485815a5
129 schema:familyName Dabisch
130 schema:givenName Inna
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074334156.67
132 rdf:type schema:Person
133 sg:person.01246054426.47 schema:affiliation https://www.grid.ac/institutes/grid.424277.0
134 schema:familyName Ruof
135 schema:givenName Jörg
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246054426.47
137 rdf:type schema:Person
138 sg:person.01247654747.73 schema:affiliation https://www.grid.ac/institutes/grid.420061.1
139 schema:familyName Drechsler
140 schema:givenName Melanie
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247654747.73
142 rdf:type schema:Person
143 sg:person.01307316670.12 schema:affiliation https://www.grid.ac/institutes/grid.435900.b
144 schema:familyName Langer
145 schema:givenName Frank
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307316670.12
147 rdf:type schema:Person
148 sg:person.01310476327.89 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
149 schema:familyName Wirth
150 schema:givenName Daniel
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89
152 rdf:type schema:Person
153 sg:person.01352546532.30 schema:affiliation https://www.grid.ac/institutes/grid.420105.2
154 schema:familyName Dethling
155 schema:givenName Jürgen
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352546532.30
157 rdf:type schema:Person
158 sg:person.0720442760.21 schema:affiliation https://www.grid.ac/institutes/grid.476393.c
159 schema:familyName Kalanovic
160 schema:givenName Daniel
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720442760.21
162 rdf:type schema:Person
163 sg:person.0763746656.45 schema:affiliation Nf3051a53137941a396043d862a62ce2b
164 schema:familyName Ruppert
165 schema:givenName Thorsten
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763746656.45
167 rdf:type schema:Person
168 sg:person.0773616073.80 schema:affiliation https://www.grid.ac/institutes/grid.476255.7
169 schema:familyName Kaskel
170 schema:givenName Peter
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773616073.80
172 rdf:type schema:Person
173 sg:pub.10.1007/s00120-011-2713-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026621978
174 https://doi.org/10.1007/s00120-011-2713-5
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00520-012-1417-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053663300
177 https://doi.org/10.1007/s00520-012-1417-8
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s10198-010-0218-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035704636
180 https://doi.org/10.1007/s10198-010-0218-6
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/bjc.2013.145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045286767
183 https://doi.org/10.1038/bjc.2013.145
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/leu.2009.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002899527
186 https://doi.org/10.1038/leu.2009.38
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/sj.bjc.6601986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010709152
189 https://doi.org/10.1038/sj.bjc.6601986
190 rdf:type schema:CreativeWork
191 sg:pub.10.1186/1752-1947-5-429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051791591
192 https://doi.org/10.1186/1752-1947-5-429
193 rdf:type schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1077138395 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1078165983 schema:CreativeWork
196 https://doi.org/10.1002/ijc.25423 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008467674
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/0277-9536(94)90151-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046445641
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.clon.2004.06.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042113450
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.urolonc.2015.03.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017967707
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ygyno.2007.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048555210
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0959-8049(01)00371-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008444022
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1046/j.1464-410x.1999.00202.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030326537
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1056/nejmoa022457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052596157
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1093/annonc/mdj023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031646383
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1093/annonc/mdq204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038028713
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1093/annonc/mdr362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012612445
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1093/jnci/djp369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019709167
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1093/jnci/djq029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024607483
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1136/bmj.317.7161.771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015749208
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1177/1352458512448449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012944288
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1177/1352458512451660 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039600953
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1182/blood-2011-10-383711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043265594
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1185/030079905x74862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023303316
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.2003.99.078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204090
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2003.99.089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204096
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.2007.10.8407 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017750913
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2007.13.6796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038707957
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2007.15.3510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002585977
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2011.39.5558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025698429
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083397220
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2012.45.9867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038250497
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1634/theoncologist.2010-s1-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052046724
251 rdf:type schema:CreativeWork
252 https://doi.org/10.3747/co.v18is2.941 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030292939
253 rdf:type schema:CreativeWork
254 https://www.grid.ac/institutes/grid.420061.1 schema:alternateName Boehringer Ingelheim (Germany)
255 schema:name Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, KG, Germany
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.420105.2 schema:alternateName GlaxoSmithKline (Germany)
258 schema:name GlaxoSmithKline GmbH & Co., Munich, KG, Germany
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.424277.0 schema:alternateName Roche (Germany)
261 schema:name Roche Pharma AG, Grenzach-Wyhlen, Germany
262 rdf:type schema:Organization
263 https://www.grid.ac/institutes/grid.435900.b schema:alternateName Eli Lilly (Germany)
264 schema:name Lilly Deutschland GmbH, Bad Homburg, Germany
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.476255.7 schema:alternateName MSD (Germany)
267 schema:name MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540, Haar, Germany
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.476393.c schema:alternateName Pfizer (Germany)
270 schema:name Pfizer Pharma GmbH, Berlin, Germany
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
273 schema:name Janssen-Cilag GmbH, Neuss, Germany
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...